• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday

    6/28/22 4:23:47 AM ET
    $AFIB
    $AGRX
    $AGTC
    $AMST
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFIB alert in real time by email

    Gainers

    • Evofem Biosciences, Inc. (NASDAQ:EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.
    • Acutus Medical, Inc. (NASDAQ:AFIB) climbed 87.6% to close at $1.01 after the company announced the commercial launch of its left-heart access products.
    • Epizyme, Inc. (NASDAQ:EPZM) jumped 55.1% to close at $1.48. Ipsen SA (OTC:IPSEY) agreed to acquire Epizyme at $1.45 per share for approximately $247 million, plus one contingent value right (CVR) per share.
    • Axsome Therapeutics, Inc. (NASDAQ:AXSM) shares surged 51.4% to settle at $37.03 after the company received proposed labeling from the U.S. Food and Drug Administration for its treatment of major depressive disorder.
    • NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) surged 48.8% to close at $2.50 after the company reported results from a stage III ALS Biomarker study evaluating PrimeC. Preliminary results showed levels of disease-related biomarkers in people with ALS were steady, in contrast to a statistically significant decline portrayed in biomarkers when PrimeC was administered.
    • Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) climbed 42.4% to close at $1.31 on Monday.
    • InflaRx N.V. (NASDAQ:IFRX) shares climbed 38.3% to close at $0.8900 after tumbling around 34% on Friday.
    • Kiromic BioPharma, Inc. (NASDAQ:KRBP) jumped 36.1% to close at $0.4901 after dropping more than 25% on Friday. Kiromic BioPharma recently announced a strategic pipeline shift to prioritize its allogeneic, non-engineered off-the-shelf product candidate, Deltacel/KB-GDT.
    • Aspira Women's Health Inc. (NASDAQ:AWH) jumped 32.4% to close at $0.6810.
    • Visionary Education Technology Holdings Group Inc. (NASDAQ:VEDU) gained 33.2% to close at $2.61.
    • Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) climbed 32.1% to close at $0.4360.
    • Femasys Inc. (NASDAQ:FEMY) gained 30.9% to settle at $2.46. Maxim Group recently initiated coverage on Femasys with a Buy rating and announced a price target of $5.
    • Marker Therapeutics, Inc. (NASDAQ:MRKR) jumped 30.8% to close at $0.34.
    • Marker Therapeutics, last month, posted a Q1 net loss of $9.9 million.
    • Landos Biopharma, Inc. (NASDAQ:LABP) climbed 29.5% to settle at $0.79. Landos recently named Gregory Oakes as President and Chief Executive Officer.
    • Nutriband Inc. (NASDAQ:NTRB) rose 27% to close at $4.98.
    • Entrada Therapeutics, Inc. (NASDAQ:TRDA) gained 26.7% to close at $12.43.
    • Sigma Labs, Inc. (NASDAQ:SASI) rose 26.4% to close at $1.39.
    • Benitec Biopharma Inc. (NASDAQ:BNTC) gained 26.2% to close at $1.54.
    • RedHill Biopharma Ltd. (NASDAQ:RDHL) climbed 24.4% to close at $1.02. RedHill Biopharma recently announced a cost reduction plan expected to generate operational cost savings of approximately $50 million over the next 18 months.
    • Tenax Therapeutics, Inc. (NASDAQ:TENX) jumped 24.1% to close at $0.3852 after dipping more than 46% on Friday.
    • Sera Prognostics, Inc. (NASDAQ:SERA) gained 23.4% to settle at $2.16.
    • Scholar Rock Holding Corporation (NASDAQ:SRRK) surged 23.2% to close at $7.34 following the purchase of 1,497,490 shares and warrants by a company director, which was disclosed late Friday.
    • The9 Limited (NASDAQ:NCTY) gained 23.2% to close at $2.02.
    • Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) jumped 23% to close at $1.07.
    • Panbela Therapeutics, Inc. (NASDAQ:PBLA) gained 22.4% to close at $0.7490.
    • Precision BioSciences, Inc. (NASDAQ:DTIL) surged 22.1% to close at $1.77. The company announced the closing of an underwritten offering for total gross proceeds of approximately $50 million.
    • Omeros Corporation (NASDAQ:OMER) jumped 21.8% to settle at $3.18.
    • Fast Radius, Inc. (NASDAQ:FSRD) gained 21% to close at $0.5150.
    • T2 Biosystems, Inc. (NASDAQ:TTOO) rose 20.7% to close at $0.1810.
    • NextPlay Technologies, Inc. (NASDAQ:NXTP) surged 20.1% to close at $0.4378.
    • Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) rose 19.6% to close at $1.22.
    • Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) jumped 19.4% to close at $4.30.
    • Virgin Orbit Holdings, Inc. (NASDAQ:VORB) rose 19.2% to close at $3.85 after the company received approval to conduct space launch operations out of Brazil.
    • Applied Genetic Technologies Corporation (NASDAQ:AGTC) shares gained 19.1% to close at $0.7350 following a 25% drop on Friday.
    • AppTech Payments Corp. (NASDAQ:APCX) gained 18.8% to close at $0.7489.
    • Amesite Inc. (NASDAQ:AMST) jumped 18.7% to close at $0.5102.
    • Remark Holdings, Inc. (NASDAQ:MARK) climbed 18.3% to close at $0.4495.
    • NuZee, Inc. (NASDAQ:NUZE) rose 18.1% to close at $1.01.
    • Alpha Teknova, Inc. (NASDAQ:TKNO) gained 18% to close at $10.21.
    • Hillstream BioPharma, Inc. (NASDAQ:HILS) rose 17.7% to close at $0.8900 after the company announced a collaboration with Sapien Biosciences in cancer treatments to evaluate the synergy of HSB-1216 with immune checkpoint inhibitors.
    • Alaunos Therapeutics, Inc. (NASDAQ:TCRT) gained 17.3% to close at $1.10. Alaunos Therapeutics and The National Cancer Institute extended cooperative research and development agreement for development of personalized TCR-T Cell therapies to 2025.
    • Ebang International Holdings Inc. (NASDAQ:EBON) gained 17.1% to close at $0.4340. Ebang International announced the receipt of Nasdaq notification regarding minimum bid price deficiency.
    • XORTX Therapeutics Inc. (NASDAQ:XRTX) rose 17.1% to close at $1.44.
    • Aptinyx Inc. (NASDAQ:APTX) jumped 16.8% to close at $0.52.
    • Creatd, Inc. (NASDAQ:CRTD) gained 16.6% to settle at $0.8671.
    • Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) jumped 16.5% to settle at $0.70.
    • Northern Lights Acquisition Corp. (NASDAQ:NLIT) rose 16.5% to close at $9.26.
    • ProQR Therapeutics N.V. (NASDAQ:PRQR) gained 16.3% to close at $0.7905.
    • Healthcare Triangle, Inc. (NASDAQ:HCTI) jumped 16% to close at $1.16.
    • FedNat Holding Company (NASDAQ:FNHC) gained 15.5% to close at $0.3004 after dipping over 20% on Friday. FedNat, last month, announced a $15 million investment by Hale Partnership in Monarch National Insurance Company.
    • Altamira Therapeutics Ltd. (NASDAQ:CYTO) rose 11.6% to close at $0.5701.
    • Reed's, Inc. (NASDAQ:REED) rose 11.4% to close at $0.1559 after dropping more than 20% on Friday. Reed's, last month, posted a Q1 loss of $0.05 per share.
    • Agile Therapeutics, Inc. (NASDAQ:AGRX) gained 10.4% to close at $1.27 amid the Supreme Court overturning Roe V Wade.
    • Martin Midstream Partners L.P. (NASDAQ:MMLP) shares rose 9.6% to close at $4.00. Martin Midstream Partners recently filed for mixed shelf of up to $250 million.
    • Armata Pharmaceuticals, Inc. (NYSE:ARMP) rose 9% to close at $3.65.
    • Clene Inc. (NASDAQ:CLNN) rose 6.9% to close at $3.10. Clene, last month, received a $3 million loan from the Maryland Board of Public Works to support production for its lead drug candidate CNM-Au8.


    Losers

    • Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS) fell 35% to close at $0.67.
    • Borqs Technologies, Inc. (NASDAQ:BRQS) shares dipped 24.4% to close at $2.15 on Monday following effect of 1:16 reverse stock split.
    • Enochian Biosciences, Inc. (NASDAQ:ENOB) dropped 21.9% to close at $2.60.
    • Anghami Inc. (NASDAQ:ANGH) dropped 21.7% to close at $5.01.
    • PetVivo Holdings, Inc. (NASDAQ:PETV) declined 21.3% to close at $2.07.
    • GreenLight Biosciences Holdings (NASDAQ:GRNA) fell 21% to close at $2.15.
    • HilleVax, Inc. (NASDAQ:HLVX) dropped 20.6% to close at $11.15. HilleVax recently reported a Q1 net loss of $67.9 million.
    • View, Inc. (NASDAQ:VIEW) fell 20.1% to settle at $1.51. View recently reported first-quarter FY22 revenue growth of 74% year-on-year to $17 million.
    • PLAYSTUDIOS, Inc. (NASDAQ:MYPS) fell 18.1% to close at $4.44.
    • Benson Hill, Inc. (NASDAQ:BHIL) fell 17.5% to close at $2.73.
    • Momentus Inc. (NASDAQ:MNTS) dipped 17.1% to close at $2.04.
    • Accelerate Diagnostics, Inc. (NASDAQ:AXDX) fell 16.9% to close at $1.13.
    • Science 37 Holdings, Inc. (NASDAQ:SNCE) dipped 16.8% to close at $2.37.
    • SIGA Technologies, Inc. (NASDAQ:SIGA) fell 16.6% to settle at $10.88. SIGA Technologies recently announced approximately $13 million in procurement orders for oral TPOXX (tecovirimat).
    • Eargo, Inc. (NASDAQ:EAR) declined 16% to close at $1.05. Eargo strengthened financial position with up to $125 million strategic investment from Patient Square Capital.
    • Zhong Yang Financial Group Limited (NASDAQ:TOP) dropped 16% to close at $29.29.
    • Quantum-Si incorporated (NASDAQ:QSI) dipped 15.9% to settle at $2.43.
    • Revlon, Inc. (NYSE:REV) fell 15.7% to settle at $6.70.
    • GeoVax Labs, Inc. (NASDAQ:GOVX) fell 15.1% to close at $1.07.
    • Bird Global, Inc. (NYSE:BRDS) dipped 15% to settle at $0.4731. Bird received notice of non-compliance with NYSE trading share price listing rule.
    • Polestar Automotive Holding UK PLC (NASDAQ:PSNY) fell 14.5% to close at $11.11 amid post-SPAC merger volatility following the company's Friday debut as a public company.
    • BioAtla, Inc. (NASDAQ:BCAB) dipped 13.8% to close at $3.06.
    • Weber Inc. (NYSE:WEBR) dropped 13.8% to settle at $8.24.
    • Digital Ally, Inc. (NASDAQ:DGLY) fell 13.1% to close at $0.8250.
    • Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) fell 8.7% to close at $2.94.
    • Sharecare, Inc. (NASDAQ:SHCR) shares fell 8.3% to close at $1.76. Sharecare, last month, reported better-than-expected Q1 EPS and sales results, issued Q2 and FY22 guidance and reported a $50 million buyback.
    • Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) slipped 5.4% to close at $1.77. Tonix Pharmaceuticals recently reported pricing of $30 million private placement of convertible redeemable preferred stock.
    Get the next $AFIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFIB
    $AGRX
    $AGTC
    $AMST

    CompanyDatePrice TargetRatingAnalyst
    Tenax Therapeutics Inc.
    $TENX
    3/17/2026$35.00Overweight
    Cantor Fitzgerald
    PLAYSTUDIOS Inc.
    $MYPS
    3/17/2026Speculative Buy → Hold
    The Benchmark Company
    ProQR Therapeutics N.V.
    $PRQR
    3/12/2026$9.00Outperform
    Oppenheimer
    Axsome Therapeutics Inc.
    $AXSM
    2/24/2026$230.00Outperform
    Wolfe Research
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Entrada Therapeutics Inc.
    $TRDA
    2/11/2026$20.00Buy
    Guggenheim
    Entrada Therapeutics Inc.
    $TRDA
    1/28/2026$21.00Outperform
    Oppenheimer
    BioAtla Inc.
    $BCAB
    1/13/2026$4.00Buy
    Rodman & Renshaw
    More analyst ratings

    $AFIB
    $AGRX
    $AGTC
    $AMST
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TAZVERIK issued to EPIZYME INC

    Submission status for EPIZYME INC's drug TAZVERIK (SUPPL-5) with active ingredient TAZEMETOSTAT HYDROBROMIDE has changed to 'Approval' on 08/13/2024. Application Category: NDA, Application Number: 211723, Application Classification: Labeling

    8/14/24 4:43:30 AM ET
    $EPZM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for TAZVERIK issued to EPIZYME INC

    Submission status for EPIZYME INC's drug TAZVERIK (SUPPL-4) with active ingredient TAZEMETOSTAT HYDROBROMIDE has changed to 'Approval' on 11/16/2023. Application Category: NDA, Application Number: 211723, Application Classification: Labeling

    11/17/23 4:37:35 AM ET
    $EPZM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for AUVELITY issued to AXSOME THERAPEUTICS, INC.

    Submission status for AXSOME THERAPEUTICS, INC.'s drug AUVELITY (ORIG-1) with active ingredient DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE has changed to 'Approval' on 08/18/2022. Application Category: NDA, Application Number: 215430, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    8/19/22 12:36:14 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $AGRX
    $AGTC
    $AMST
    SEC Filings

    View All

    Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

    3/18/26 6:01:48 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precision BioSciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)

    3/17/26 8:31:07 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Clene Inc.

    10-K - Clene Inc. (0001822791) (Filer)

    3/17/26 7:00:40 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $AGRX
    $AGTC
    $AMST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner A.L. Sarroff Fund, Llc bought 1,250,000 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    3/13/26 5:10:25 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Lowell Matthew bought $87,616 worth of shares (40,000 units at $2.19), increasing direct ownership by 31% to 168,376 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    3/9/26 4:30:28 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Gunstream Stephen bought $55,801 worth of shares (26,000 units at $2.15), increasing direct ownership by 11% to 269,497 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    3/9/26 4:24:28 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AFIB
    $AGRX
    $AGTC
    $AMST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

    Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial"CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that Dr. Christian Lunetta will present new data and insights on the development of PrimeC, the company's investigational therapy for amyotrophic lateral sclerosis (ALS), at the AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disord

    3/18/26 8:00:00 AM ET
    $NRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Momentus Awarded NASA Contract to Design Solar Sail Demonstration Mission

    Momentus Inc. (NASDAQ:MNTS), a U.S. commercial space company offering satellites, satellite components, and in-space transportation and hosted payload services, today announced that it was awarded a NASA contract to support the Space Storms Solar Sail Sentinel Demonstration Study for a potential mission based on the cislunar-capable Vigoride spacecraft platform. Momentus recently completed this study and submitted the final report to NASA under this contract awarded in 2025. After reviewing the results of this study, NASA may consider awarding a follow-on contract to conduct further study or a flight demonstration of the solar sail through the Flight Opportunities program, managed at NASA

    3/18/26 8:00:00 AM ET
    $MNTS
    Military/Government/Technical
    Industrials

    Houston Astros Enter Multi-Year Renewal and Expansion of Partnership with Evolv Technology

    New subscription agreement upgrades all Evolv Express® units to Gen2 hardware, Astros first professional baseball team to deploy Evolv eXpedite™ bag screening systems Evolv Technologies Holdings, Inc. (NASDAQ:EVLV), a leading security technology company pioneering AI-based solutions designed to create safer experiences, today announced that it has renewed and expanded its subscription agreement with the Houston Astros, a Major League Baseball team. Under the new agreement, which builds on an original partnership initiated in 2023, the Astros are upgrading their Express fleet to the latest Evolv Express® Gen2 hardware. Evolv Express uses advanced sensor technology and AI to detect conceale

    3/18/26 8:00:00 AM ET
    $EVLV
    Computer peripheral equipment
    Technology

    $AFIB
    $AGRX
    $AGTC
    $AMST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Kyme Pierre covered exercise/tax liability with 1,030 shares, decreasing direct ownership by 10% to 9,461 units (SEC Form 4)

    4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)

    3/17/26 7:48:27 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Birx Deborah covered exercise/tax liability with 4,919 shares, decreasing direct ownership by 2% to 212,458 units (SEC Form 4)

    4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)

    3/17/26 7:46:39 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Executive VP & CFO Luckshire Daniel J converted options into 11,503 shares and covered exercise/tax liability with 6,074 shares, increasing direct ownership by 2% to 280,493 units (SEC Form 4)

    4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

    3/17/26 4:11:14 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $AGRX
    $AGTC
    $AMST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Tenax Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $35.00

    3/17/26 8:15:05 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PLAYSTUDIOS downgraded by The Benchmark Company

    The Benchmark Company downgraded PLAYSTUDIOS from Speculative Buy to Hold

    3/17/26 7:56:59 AM ET
    $MYPS
    Computer Software: Prepackaged Software
    Technology

    Oppenheimer resumed coverage on ProQR Therapeutics with a new price target

    Oppenheimer resumed coverage of ProQR Therapeutics with a rating of Outperform and set a new price target of $9.00

    3/12/26 8:55:08 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $AGRX
    $AGTC
    $AMST
    Financials

    Live finance-specific insights

    View All

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 60,655 shares of its common stock to five newly hired employees, consisting of inducement stock options to purchase an aggregate of 24,506 shares of common stock and inducement restricted stock units, covering an aggregate of 36,149 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used

    3/13/26 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    InflaRx to Report Full Year 2025 Results on March 19, 2026

    JENA, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2025 on March 19, 2026, before the market opens. No conference call is planned. About InflaRxInflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C

    3/12/26 7:30:00 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Reed's Schedules Fourth Quarter & Full Year 2025 Conference Call for March 25 at 8:30 a.m. ET

    NORWALK, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Reed's, Inc. (NYSE:REED) ("Reed's" or the "Company"), owner of the nation's leading portfolio of handcrafted, natural ginger beverages, will host a conference call on Wednesday, March 25, 2026, at 8:30 a.m. Eastern time to discuss its financial results for the three and twelve months ended December 31, 2025. The Company's results will be reported in a press release prior to the call. Reed's management will host the conference call, followed by a question-and-answer period. Date: Wednesday, March 25, 2026Time: 8:30 a.m. Eastern timeToll-free dial-in number: (800) 717-1738International dial-in number: (646) 307-1865Conference ID: 59633Webc

    3/11/26 4:30:00 PM ET
    $REED

    $AFIB
    $AGRX
    $AGTC
    $AMST
    Leadership Updates

    Live Leadership Updates

    View All

    Evolv Technology Announces the Appointment of Henrik Kühl as a New Independent Director

    – Long-Time Member of the Board of Directors and Early Venture Capitalist Bilal Zuberi Resigns from Board – Evolv Technologies Holdings, Inc. (NASDAQ:EVLV), a leading security technology company pioneering AI-based solutions designed to create safer experiences, today announced the appointment of Mr. Henrik Kühl, age 46, to its Board of Directors ("Board") effective February 12, 2026. Kühl will also serve on the Board's Audit Committee. The Board affirmatively determined that Kühl is independent and an audit committee financial expert as that term is defined by applicable Securities and Exchange Commission regulations. Kühl is an accomplished leader with over 25 years of experience in c

    2/12/26 8:00:00 AM ET
    $AXON
    $EVLV
    Ordnance And Accessories
    Industrials
    Computer peripheral equipment
    Technology

    ProQR Announces Planned Changes to Board Composition

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company's next Annual General Meeting (AGM) as their terms conclude.  The planned changes to ProQR's Board composition at its 2026 AGM reflect the Company's development as it advances its clinical programs, as well as its ongoing commitment to strong corporate governance and long-term succession planni

    2/9/26 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

    CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that further to its press release of October 17, 2025 and an update on December 31, 2025, the Company has entered into an extension agreement with Vectus Biosystems Limited ("Vectus") to allow further time to complete the acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus (the "Acquisition"). The term sheet entered into October 17th (the "Term Sheet") to acquire the novel new chemical

    2/4/26 6:00:00 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $AGRX
    $AGTC
    $AMST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolv Technologies Holdings Inc.

    SC 13G/A - Evolv Technologies Holdings, Inc. (0001805385) (Subject)

    12/12/24 3:21:41 PM ET
    $EVLV
    Computer peripheral equipment
    Technology

    SEC Form SC 13G filed by NeuroSense Therapeutics Ltd.

    SC 13G - NeuroSense Therapeutics Ltd. (0001875091) (Subject)

    12/9/24 4:00:18 PM ET
    $NRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care